Share on StockTwits

Epizyme (NASDAQ:EPZM) CFO Jason P. Rhodes unloaded 30,000 shares of Epizyme stock on the open market in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $29.74, for a total value of $892,200.00. Following the completion of the transaction, the chief financial officer now directly owns 82,000 shares in the company, valued at approximately $2,438,680. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday, July 15th. They set a “buy” rating and a $40.00 price target on the stock. Separately, analysts at HC Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday, July 15th. They set a “buy” rating and a $40.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Epizyme from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 9th. They now have a $35.10 price target on the stock.

Shares of Epizyme (NASDAQ:EPZM) traded up 4.15% during mid-day trading on Tuesday, hitting $31.63. 266,020 shares of the company’s stock traded hands. Epizyme has a 52-week low of $18.10 and a 52-week high of $42.71. The stock’s 50-day moving average is $30.47 and its 200-day moving average is $27.17. The company’s market cap is $1.040 billion.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.47) by $0.25. Analysts expect that Epizyme will post $-1.81 EPS for the current fiscal year.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.